Nektar's Alopecia Drug Shows Promise But Raises Concerns
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.
A new medicine, rezpegaldesleukin, shows promise for moderate-to-severe eczema. It boosts special immune cells to rebalance the body and cut inflammation, leading to rapid and deeper symptom relief. It's an FDA Fast Tracked, self-injected treatment.